IPACK Nerve Block for Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2018-01-23
• Target enrollment: 0
• Participant gender: All

Summary

Double-blind, randomized controlled clinical trial to test the efficacy of IPACK on postoperative opioid consumption, patient satisfaction, pain scores, mobility, and several other secondary outcomes in adults undergoing primary unilateral TKA.

Enrolled patients will be randomized to either continuous ACB with IPACK or to continuous ACB with sham subcutaneous saline injection. Outcomes assessors and patients will be blinded to the intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ochsner Health System
• Treatments: Anesthetics; Ropivacaine

Criteria

Inclusion Criteria:

• Unilateral, primary tricompartment total knee arthroplasty

• Age 18 years or older

• ASA I-III

• Eligible for spinal or combined spinal epidural anesthetic

• Able to speak, read, and understand English

• Willing to participate in the trial

Exclusion Criteria:

• Contraindication to regional anesthesia or peripheral nerve blocks

• Allergy to local anesthetics

• Allergy to NSAIDs

• Chronic renal insufficiency with Cr > 1.4 or GFR < 60

• Have chronic pain that is not related to their knee joint

• Have been using opioids on a chronic basis (daily or almost daily opioid use for 3 months or longer)

• Have a pre-existing peripheral neuropathy involving the operative site

• Body mass index greater than or equal to 40